Novavax has filed an application with the Food and Drug Administration for Emergency Use Authorization for its COVID-19 vaccine as an adult booster that can be used in addition to or in combination with its main vaccine series. submitted. And it will match another primary series, the company announced.
"It's important to have options when evaluating ways to stay protected against COVID-19. Boosters build on immunity from previous vaccinations."
"Data presented to FDA's VRBPAC and CDC ACIP," Novavax's CEO said in a statement Monday. Based on that, we believe our vaccine will provide a broad and long-lasting immune response against different variants," said Erck.
His Novavax Covid- 19 Boxes of Vaccines, Aug. 1, 2022.
Hannah Beier/Bloomberg, Getty Images, File
After being licensed last month, 500,000 doses of the Novavax vaccine have now been distributed to states, but only 9,700 doses of the Novavax COVID-19 vaccine have been administered nationwide, according to federal data.
The slow start may be partly due to the fact that the vaccine was not available soon after it was licensed, which may delay reporting.
Last month, officials at the Centers for Disease Control and Prevention approved the use of Novavax's COVID-19 vaccine for Americans over the age of 18, making a fourth COVID-19 vaccine available. American public.
The Biden administration has secured 3.2 million doses of his COVID-19 vaccine for Novavax.
Many health experts note that some individuals who are still hesitant to vaccinate are more likely to get the Novavax vaccine because it is based on a more traditional protein-based vaccine. The technology is already being used in flu vaccines and other shots, but Pfizer and Moderna's vaccine platforms are leveraging novel genetic technology with messenger RNA to manufacture vaccines.
Early indications suggest that he has yet to persuade most of the 26 million American adults who are unvaccinated to get the vaccine. there is
Novavax Covid-19 vaccines placed in pharmacies in Schwenksville, Pennsylvania vial, 1 August 2022.
Hannah Beier/Bloomberg, Getty Images, File
However, experts say that while overall intake is still limited, some Americans who received the Moderna, Pfizer, or Johnson & Johnson COVID-19 vaccines would like to receive more. It is said that there may be people who feel it. Novavax booster.
“Vaccine options may play a role in improving vaccination coverage. Given that so many Americans have yet to receive a booster despite the fact that there are so many Americans, the improved dose of the vaccine may be somewhat limited," said an epidemiologist at Boston Children's Hospital. , said ABC News contributor Dr. John Braunstein.
Nationwide, he said more than half of the 110 million Americans who qualify for a boost did not get their first booster injection, according to CDC data.
Similarly, over the age of 50, more than 61 million people are eligible for his second COVID-19 booster, but only a third of them actually get it. Only 1.
